Teva's (TEVA -1.8%) and Active Biotech's (ATVBF.PK) oral laquinimod drug improved renal function in patients with active lupus nephritis in Phase IIa trials. Lupus is a chronic and often disabling autoimmune disease that can lead to kidney failure. Teva and Active Biotech believe the data provide the rationale for further studies of laquinimod. (PR)
Teva (TEVA +0.25%) and Active Biotech (ATVBF.PK) say that early treatment of Multiple Sclerosis with their Laquinimod drug significantly cuts the risk of disability progression in patients, a Phase III trial shows. Additional data from an animal preclinical study demonstrates that laquinimod can restore myelination in the brain and spinal cord. (PR)
Laquinimod, which is being developed by Teva (TEVA +1.2%) and Sweden's Active Biotech, performed well in a Phase IIa trial of patients with moderate to severe Crohns disease. The drug had a "robust, early and consistent effect on remission" and on response rates compared with a placebo. Laquinimod was also well-tolerated. (PR)
Teva (TEVA) and Active Biotech are set to initiate the third Phase III trial of their oral Laquinimod treatment for relapsing remitting multiple sclerosis. Two previous trials have produced positive results. Teva also nominates former Bank Leumi CEO Galia Maor as a director.
Teva (TEVA +5.6%) and Active Biotech (ATVBF.PK) announce their Phase III study of laquinimod, a drug for multiple-sclerosis, met its primary endpoint and led to a "statistically significant reduction" in relapse rates compared to a placebo.